Salah-Eddin Al-Batran: Our group is happy to announce the publication of the IKF-633/DANTE trial (phase 2 portion) in Journal of Clinical Oncology

Salah-Eddin Al-Batran, Director of IKF-The Frankfurt Institute of Clinical Cancer Research, shared on LinkedIn:

“Dear colleagues,
Our group is happy to announce the publication of the IKF-633/DANTE trial (phase 2 portion) in Journal of Clinical Oncology by Sylvie Lorenzen, Prof Dr Thorsten Götze, and colleagues. Adding the PD-L1 antibody atezolizumab to FLOT chemotherapy for patients with localized esophagogastric adenocarcinoma undergoing perioperative therapy significantly improved complete path response rates from 15% to 24% and increased down-staging after surgery with pN0 from 54% to 68%. DANTE marks the first major trial fully published on checkpoint inhibition in this context. The ongoing phase III portion is concentrating on patients with a high likelihood of responding to immunotherapy, such as those with PD-L1 positivity, MSI high status, or a high tumor mutation burden.

The study was conducted by
IKF – The Frankfurt Institute of Clinical Cancer Research
Under the labels of:
Working Group on Internal Oncology (AIO) of German Cancer Society (Arbeitsgemeinschaft Internistische Onkologie in der DKG)

Thank you very much for the support provided by
Roche, Roche Germany.”

For the paper attached to the post click here.
Source: Salah-Eddin Al-Batran/LinkedIn